化合物TG101209 T3065

Product Introduction
Bioactivity


英文名: TG101209

描述: TG101209 是一种选择性有效的 JAK2抑制剂，IC50值为 6 nM。它能抑制 Flt3和RET 的活性，IC50值分别为 25 nM 和 17 nM。

细胞实验: In brief, approximately 2 × 103 cells are plated into microtiterplate wells in 100 ml RPMI-1640 growth media with indicated concentrations of TG101209. The relative growth of cells is quantified at 24-hour intervals using Cell Proliferation Kit II (XTT) as per manufacturer's guidelines. After incubation, 20 mL of XTT is added to the wells and allowed to incubate for 4-6 hours. The colored formazan product is measured spectrophotometrically at 450 nm with correction at 650 nm, and IC50 values are determined using the GraphPad Prism 4.0 software. Data are subjected to a non-linear regression-fit analysis and IC50 values are determined as the concentration that inhibited proliferation by 50%. All experiments are done in triplicate and the results normalized to growth of untreated cells.(Only for Reference)

激酶实验: Cell-free Kinase Activity Assays: IC50 values for TG101209 are determined using a luminescence-based kinase assay with recombinant JAK2, VEGFR2/KDR, and JAK3 obtained from Upstate Cell Signaling Solutions. Kinase reactions are carried out in a buffer consisting of 40 mM Tris buffer (pH 7.4), 50 mM MgCl2, 800?M EGTA, 350?M Triton X-100, 2?M ?-mercaptoethanol, 100?M peptide substrate, and an appropriate amount of JAK2, VEGFR2/KDR or JAK3 such that the assay is linear over 60 minutes. The reaction is initiated by the addition of 10?L of ATP to a final concentration of 3 mM and terminated by the addition of Kinase-Glo reagent after 60 minutes. Luciferase activity is quantified using an Ultra 384 instrument set for luminosity measurements. IC50 values are derived from experimental data using the non-linear curve fitting capabilities of the GraphPad Prism 4.0 software. The single concentration inhibition data for a panel of 63 kinases is determined using the SelectScreen TM service.

体外活性: 与安慰剂处理的动物相比,TG101209处理的动物体内循环肿瘤细胞负荷显著减少,呈剂量依赖性,在+11天时减少比例达到20%.100 mg/kg TG101209有效延长JAK2V617F诱发的患病动物的存活时间（10天）.

体内活性: TG101209抑制HCC2429和H460肺癌细胞中存活素,并降低STAT3的磷酸化作用。TG101209在表达人JAK2V617F的急性髓细胞性白血病细胞系中,诱导细胞周期阻滞和细胞凋亡,并抑制JAK2V617F,STAT5和STAT3的磷酸化。TG101209抑制表达JAK2V617F或MPLW515L突变体的Ba/F3细胞生长,IC50为B200 nM。TG101209抑制来自携带JAK2V617F或MPL515突变的原始祖细胞的造血集落的生长。TG101209明显减少STAT5磷酸化,而不影响STAT5蛋白质的总量。TG101209消除BCR-JAK2和STAT5的磷酸化,减少Bcl-xL表达,并引发转化的Ba/F3细胞凋亡。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 94 mg/mL (184.4 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)


关键字: Cluster of differentiation antigen 135 | RET | TG101209 | Inhibitor | Janus kinase | TG-101209 | CD135 | Fms like tyrosine kinase 3 | FLT3 | Apoptosis | TG 101209 | JAK | inhibit | Autophagy

相关产品: LQZ-7F | LCH-7749944 | 9-dihydro-13-acetylbaccatin III | α-Thujone | PTC-028 | 1-Monopalmitin | CHIR-124 | BTR-1 | Polyinosinic-polycytidylic acid sodium | Pectolinarin

相关库: JAK-STAT Compound Library | Anti-Prostate Cancer Compound Library | Anti-Liver Cancer Compound Library | Angiogenesis related Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library

化合物TG101209 T3065信息由TargetMol中国为您提供，如您想了解更多关于化合物TG101209 T3065报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途